NVS
Novartis·NYSE
--
--(--)
--
--(--)
NVS Filings
Filing Date
Form Description
Form Type
2026-03-18
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Key Events
2026-03-18 · Key Events
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2026-03-17
Form 424B5 - Prospectus [Rule 424(b)(5)]
2026-03-17 ·
Form 424B5 - Prospectus [Rule 424(b)(5)]
2026-03-17
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2026-03-17 ·
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2026-03-16
Form 424B5 - Prospectus [Rule 424(b)(5)]
2026-03-16 ·
Form 424B5 - Prospectus [Rule 424(b)(5)]
2026-02-12
Form 144 - Report of proposed sale of securities
Ownership
2026-02-12 · Ownership
Form 144 - Report of proposed sale of securities
2026-02-09
Form 144 - Report of proposed sale of securities
Ownership
2026-02-09 · Ownership
Form 144 - Report of proposed sale of securities
2026-02-04
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Earnings Call
2026-02-04 · Earnings Call
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
2026-02-04
Form S-8 - Securities to be offered to employees in employee benefit plans
Ownership
2026-02-04 · Ownership
Form S-8 - Securities to be offered to employees in employee benefit plans
2026-02-04
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Key Events
2026-02-04 · Key Events
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2026-02-04
Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).
2026-02-04 ·
Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).
